Adimmune Corporation (TPE:4142)

Market Cap	7.69B -20.7%
Revenue (ttm)	1.20B -23.6%
Net Income	-508.60M
EPS	-1.21
Shares Out	421.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,079,762
Average Volume	3,124,410
Open	18.05
Previous Close	18.25
Day's Range	17.80 - 18.15
52-Week Range	15.90 - 25.75
Beta	0.47
RSI	33.63
Earnings Date	Mar 27, 2026

About Adimmune

Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1965
• Employees: 564
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4142

Financial Performance

In 2024, Adimmune's revenue was 1.56 billion, a decrease of -12.78% compared to the previous year's 1.79 billion. Losses were -242.75 million, -62.06% less than in 2023.